Literature DB >> 15743975

In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.

Nicolas Picard1, Thierry Cresteil, Nassim Djebli, Pierre Marquet.   

Abstract

Buprenorphine (BUP) is a synthetic derivative of the morphine alkaloid thebaine. BUP is metabolized by N-dealkylation to form the active metabolite nor-buprenorphine (Nor-BUP), and both undergo subsequent glucuronidation. Although BUP has been used clinically for years, its metabolism has still not been fully elucidated. The aim of this study was to clarify the identity of the human hepatic cytochromes P450 (P450s) involved in BUP metabolism and to investigate other potential metabolites. The metabolism of BUP was examined using human liver microsomes (HLM) and Ad293 P450-transfected cell lines, as well as CYP 3A4 and 2C8 recombinant isoforms. The kinetic parameters of metabolite formation were calculated for HLM and competent isoforms. Individual contribution of P450 isoforms in BUP metabolism as well as Nor-BUP production was evaluated using chemical inhibition experiments, as well as the relative activity factor approach. The analytical method used was based on liquid chromatography-mass spectrometry. Among the 13 P450 isoforms tested, CYP 3A4, 2C8, 3A5, and 3A7 produced Nor-BUP. Based on the results of chemical inhibition, CYP 3A4 accounts for about 65% of Nor-BUP production and CYP 2C8 for about 30%. BUP utilization by either HLM or P450-transfected cells revealed that another oxidative metabolic pathway exists, which was found to involve CYP 2C9, 2C18, 2C19, and mainly CYP 3A. Incubation of BUP or Nor-BUP with HLM led to the formation of new metabolites, identified by tandem mass spectrometry as being hydroxy-BUP and hydroxy-Nor-BUP. Hydroxy-BUP was produced by the CYP 3A, but not the 2C isoforms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743975     DOI: 10.1124/dmd.105.003681

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  41 in total

1.  Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Authors:  David E Moody; Wenfang B Fang; Jerdravee Morrison; Elinore McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

2.  Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium.

Authors:  Sherri L Kacinko; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Chem       Date:  2007-11-29       Impact factor: 6.986

Review 3.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 4.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

Review 5.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

6.  Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy.

Authors:  David Joseph; Michael J Schobelock; Robert R Riesenberg; Bradley D Vince; Lynn R Webster; Abidemi Adeniji; Mabrouk Elgadi; Fenglei Huang
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

7.  Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes.

Authors:  Stephanie Bomsien; Rolf Aderjan; Rainer Mattern; Gisela Skopp
Journal:  Eur J Clin Pharmacol       Date:  2006-06-27       Impact factor: 2.953

Review 8.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

9.  In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.

Authors:  Bryce A Griffin; Caitlin O Caperton; Lauren N Russell; Christian V Cabanlong; Catheryn D Wilson; Kyle R Urquhart; Bradford S Martins; Marcelle Dina Zita; Amy L Patton; Alexander W Alund; S Michael Owens; William E Fantegrossi; Jeffery H Moran; Lisa K Brents
Journal:  J Pharmacol Exp Ther       Date:  2019-04-26       Impact factor: 4.030

10.  Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.

Authors:  S L Kacinko; H E Jones; R E Johnson; R E Choo; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2008-08-13       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.